The record
| Class | ghrh analog |
|---|---|
| Also known as | - |
| Chain length | - |
| Molecular weight | 3,647.25 Da |
| Half-life | 6-8 days |
| Route | - |
| Studied for | - |
| Research use | - |
| What has been shown | - |
| How it works | GHRH analog with maleimide-albumin conjugate for extended half-life |
| Patent status | - |
| Regulatory status | - |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 56%)
- GH Pulsatility Environment (affection, 85%)
- Adult GH deficiency (illness, 60%)
- Anti-aging protocols (illness, 40%)
- Anti-aging therapy (illness, 60%)
- Body composition optimization (illness, 48%)
- Cognitive support (illness, 30%)
- Duchenne muscular dystrophy (illness, 30%)
- Growth hormone deficiency (illness, 40%)
- HIV-associated lipodystrophy (illness, 30%)
- Metabolic syndrome (illness, 40%)
- Neuromuscular diseases (illness, 30%)
- Pediatric growth hormone deficiency (illness, 60%)
- Visceral adiposity reduction (illness, 30%)
- Muscle loss or weakness (symptom, 67%)